UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
12
March 2026 – “Commencement of £500m Share Buyback
Programme”
|
99.1
Haleon plc: Commencement
of £500m Share Buyback Programme
12 March 2026: Haleon
plc (the "Company", or "Haleon") today announces that, as set out
in the 2025 preliminary full year results announcement on 25
February 2026, it is commencing a share buyback programme to
purchase ordinary shares of £0.01 each in the Company (the
"Shares") up to an aggregate consideration of £500 million
(the "Buyback Programme"), in line with its stated capital
allocation priorities, including delivering attractive shareholder
returns.
In connection with the Buyback Programme, the Company has entered
into an irrevocable agreement with HSBC Bank plc ("HSBC") for the
purchase of Shares. Under the terms of this agreement, any
purchases will be carried out on the London Stock Exchange, CBoE
Equities Europe, and/or Aquis.
HSBC will make its trading decisions independently of Haleon,
including with respect to the timing of purchases and during any
closed period.
Purchases made under the Buyback Programme prior to the Company's
2026 Annual General Meeting will be effected pursuant to the
authority granted by shareholders at the 2025 AGM. Any purchases
made following the 2026 AGM will be effected pursuant to the
authority being sought from shareholders at that meeting, if
approved.
The Buyback Programme will commence immediately and end no later
than 19 August 2026. All Shares purchased by the Company under the
Buyback Programme will be cancelled and the purpose is to reduce
the Company's share capital.
Notes
The maximum number of Shares that may be purchased as part of the
Buyback Programme under the Company's existing authority obtained
at its Annual General Meeting held on 28 May 2025 (the "2025
Authority") is 803,994,107, being the amount of the 2025 Authority
not yet utilised as at the date of this announcement. The Company
intends to seek shareholder approval for share buybacks of up to
10% of the Company's issued share capital at the Company's upcoming
Annual General Meeting to be held in April 2026 (the "2026
Authority").
Any purchases of Shares under the Buyback Programme contemplated by
this announcement will be effected within certain pre-set
parameters and will be subject to the terms of the arrangement with
HSBC. The Buyback Programme will operate in accordance with (i) the
2025 Authority or the 2026 Authority (as applicable); (ii) the
assimilated UK Market Abuse Regulation No. 596/2014 and assimilated
Commission Delegated Regulation (EU) 2016/1052 (in each case as
they form part of law of the United Kingdom by virtue of the
European Union (Withdrawal) Act 2018) (as amended) and (iii)
Chapter 9 of the UK Financial Conduct Authority's UK Listing
Rules.
There is no guarantee that the Buyback Programme will be
implemented in full or of the number of Shares that will be bought
back by the Company. The Company will make further regulatory
announcements in respect of purchases of Shares under the Buyback
Programme as they occur.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
||
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
March 12, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|